Dermoscopic evaluation of therapeutic response to an intralesional corticosteroid in the treatment of alopecia areata

Ganjoo, Shikhar; Thappa, Devinder Mohan

doi:10.4103/0378-6323.110767

Cited by 39 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thappa et al preferred tincture iodine and anthralin as first line. [65] Long-term use of systemic steroids is generally not recommended because of potential side effects. Psychological effects are of major concern in children, and they should be attended to with proper counseling.…”

Section: Miscellaneous Miscellaneousmentioning

confidence: 99%

“…[109] Tincture iodine has been suggested as a non-specific irritant in patchy AA patients with less than 10 years of age. [65] Topical bexarotene 1% gel was evaluated in single-blinded half head study and found 50% or more partial regrowth in 12% of patients on the treated side and in 14% responded on both sides. [95] Fractional Er: Glass laser has shown complete hair regrowth in a single patient who was not responding to conventional therapies.…”

Section: Miscellaneous Miscellaneousmentioning

confidence: 99%

“…Thappa et al used it as a primary choice in the treatment of patchy AA in children <10 years of age. [65] Anthralin was found effective in 75% of patchy AA and 25% of AT patients. [64] It may produce severe irritation, folliculitis, regional lymphadenopathy, and staining of skin, clothes, and hair.…”

Section: Minoxidil Minoxidilmentioning

confidence: 99%

“…[64] They can be applied alternate day or 5 days a week to prevent atrophy. [65] Application under occlusion increases the potency of topical corticosteroids and in turn side effects. [9,29] Younger age of onset Family history of AA Atopy Severe disease-AT/AU Ophiasis Duration >1 year Nail disease Associated autoimmune disease Intralesional corticosteroids have been used since 1958 in the treatment of AA, and it is the treatment of choice for adults in patchy AA, with approximate success rates of 60-75%.…”

Section: Corticosteroids Corticosteroidsmentioning

confidence: 99%

“…[68] ANTHRALIN ANTHRALIN Anthralin is an irritant, and it's mechanism of action in AA is unknown. It is effective because of its Corticosteroids [5,29,[63][64][65] Corticosteroids [63][64][65][78][79][80][81][82][83][84][85][86][87] Cyclosporine A [91] Calcineurin inhibitors [97,98] Minoxidil [66][67][68] Sulfasalazine [88,89] Methotrexate [92] Biologicals [99,100] Anthralin [5,65] PUVA [90] Azathioprine [93] NBUVB [101] Immunotherapy [69][70][71][72] Capsaicin [94] Phototherapy [73,74] Topical bexarotene 1% gel [95] Prostaglandin analogues [75][76][77] Camoufl age [96] immunosuppressive and anti-inflammatory properties by generating free radicals. [5] It...…”

Section: Minoxidil Minoxidilmentioning

confidence: 99%

See 4 more Smart Citations

Alopecia areata: An update

Seetharam¹

2013

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

Alopecia areata (AA) is a common form of non-scarring hair loss of scalp and/or body. Genetic predisposition, autoimmunity, and environmental factors play a major role in the etiopathogenesis of AA. Patchy AA is the most common form. Atopy and autoimmune thyroiditis are most common associated conditions. Peribulbar and intrabulbar lymphocytic inflammatory infiltrate resembling "swarm of bees" is characteristic on histopathology. Treatment is mainly focused to contain the disease activity. Corticosteroids are the preferred treatments in form of topical, intralesional, or systemic therapy. Camouflage in the form of wigs may be an alternative option in refractory cases.

show abstract

Section: Miscellaneous Miscellaneousmentioning

confidence: 99%

Section: Miscellaneous Miscellaneousmentioning

confidence: 99%

Section: Minoxidil Minoxidilmentioning

confidence: 99%

Section: Corticosteroids Corticosteroidsmentioning

confidence: 99%

Section: Minoxidil Minoxidilmentioning

confidence: 99%

See 3 more Smart Citations

Alopecia areata: An update

Seetharam¹

2013

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

show abstract

Comparative study between topical steroid alone versus combined fractional Erbium:YAG laser with topical steroid in treatment of alopecia areata

Shokeir

Yousry²,

Ibrahim³

2022

Arch Dermatol Res

View full text Add to dashboard Cite

Introduction: AA is a common autoimmune skin disease that causes hair loss on the scalp and sometimes other areas of the body.Background and Objectives: New therapy approaches for alopecia areata are emerging, with the goal of improving clinical outcomes. In this study, the effects of topical steroids against fractional Er: YAG laser followed by topical steroids in the treatment of alopecia areata will be compared.Methods: A total of 30 participants with alopecia areata were included in the study. Each patient's lesions were treated with one of two methods: topical clobetasol propionate or fractional Er: YAG laser followed by topical clobetasol propionate. SALT score, patient satisfaction, and dermoscopic imaging were used to evaluate therapeutic response.Results: Both treatment modalities showed a signi cant clinical improvement in alopecia areata with a statistically signi cant reduction in the SALT score. The SALT score was more evident in the laser-steroid group. On comparing the dermoscopy ndings in both treated areas before and after treatment, a signi cant reduction was found regarding all dermoscopic ndings of alopecia areata in both modalities.

show abstract